XENE
Xenon Pharmaceuticals Inc.
$35.34
-3.18%
2026-10-23
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Key Fundamentals
Forward P/E
-7.84
EPS (TTM)
$-4.74
ROE
-43.6%
Profit Margin
0.0%
Debt/Equity
0.52
Price/Book
2.88
Beta
0.62
Market Cap
$3.58B
Avg Volume (10D)
3.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$66.40
60D Low
$33.38
Avg Volume
1.5M
Latest Close
$35.34
Get breakout alerts for XENE
Sign up for Breakout Scanner to receive daily notifications when XENE triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Xenon Pharmaceuticals Inc. (XENE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors XENE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. XENE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.